KR920703078A - 인터로이킨-2 및 히스타민, 이것의 유사물 또는 h₂-리셉터 작동약을 포함하는 항종양 제제 - Google Patents

인터로이킨-2 및 히스타민, 이것의 유사물 또는 h₂-리셉터 작동약을 포함하는 항종양 제제

Info

Publication number
KR920703078A
KR920703078A KR1019920700628A KR920700628A KR920703078A KR 920703078 A KR920703078 A KR 920703078A KR 1019920700628 A KR1019920700628 A KR 1019920700628A KR 920700628 A KR920700628 A KR 920700628A KR 920703078 A KR920703078 A KR 920703078A
Authority
KR
South Korea
Prior art keywords
histamine
composition
agent
therapeutic agent
enzymes
Prior art date
Application number
KR1019920700628A
Other languages
English (en)
Other versions
KR100195392B1 (ko
Inventor
크리스토퍼 헬스트랜드 얀
헤르모드손 스반테
Original Assignee
크리스토퍼 헬스트랜드 얀
헤르모드손 스반테
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스토퍼 헬스트랜드 얀, 헤르모드손 스반테 filed Critical 크리스토퍼 헬스트랜드 얀
Publication of KR920703078A publication Critical patent/KR920703078A/ko
Application granted granted Critical
Publication of KR100195392B1 publication Critical patent/KR100195392B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

인터로이킨-2 및 히스타민, 이것의 유사물 또는 H₂-리셉터 작동약을 포함하는 항종양 제제
[도면의 간단한 설명]
본 도면은, 수컷 새앙쥐의 여러 처리에 의해 산출된 B16 색소 세포종 세포의 폐 전이 병소수를 보여주는 히스토그램이다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 악성 종양 세포의 전이 효소 및 종양 성장을 억제하는 제약학적 제제 또는 시스템에 있어서, 히스타민, H2-리셉터 활성을 지닌 이것의 유사체, 내인성 히스타민 방출 제제 및 H2-리셉터 작동약으로 구성된 군으로부터 선택된 치료제를 포함하는 제1조성물과, IL-2를 포함하는 제2조성물로 구성되며, 상기 제1조성물 및 제2조성물은 악성 종양 세포의 전이 효소 및 종양을 치료하기에 충분한 양으로 제제 중에서 서로 혼합되거나 혹은 서로 분리된 용량으로 제조되는 것을 특징으로 하는, 악성 종양 세포의 전이 효소 및 종양 성장을 억제하기 위한 제약학적 제제 또는 시스템.
  2. 제1항에 있어서, 상기 치료제의 1일 용량은 0.1 내지 10mg, 바람직하게 0.5 내지 8mg, 더욱 바람직하게는 1 내지 5mg인 것을 특징으로 하는 제약학적 제제 또는 시스템.
  3. 제1항 또는 제2항에 있어서, IL-2의 일일 용량은 1,000 내지 300,000U/kg 바람직하게는 3,000 내지 100,000U/kg 더욱 바람직하게는 5,000 내지 20,000/kg인 것을 특징으로 하는 제약학적 제제 또는 시스템.
  4. 제1항에 있어서, 상기 치료제는 히스타민인 것을 특징으로 하는 제약학적 제제 또는 시스템.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, 용매, 분산매체, 피복물, 살균제, 등장제 및 흡수 지연제등과 같은 하나 이상의 제약학적 허용 담체를 함유하는 것을 특징으로 하는 제약학적 제제 또는 시스템.
  6. 히스타민, H2-리셉터 활성을 지닌 이것의 유사체, 내인성 히스타민 방출 제제 및 H2-리셉터 작동약으로 구성된 군으로 부터 선택된 치료제를 포함하는 제1조성물과 IL-2를 포함하는 제2조성물을 악성 종양 세포의 전이 효소 및 종양 성장을 치료하기에 충분한 양으로 제제 중에 서로 혼합하거나, 혹은 분리된 용량으로 제조함으로써 악성 종양 세포의 전이 효소와 종양 성장을 억제하기 위한 제약학적 제제 또는 시스템을 제조하는데 히스타민, H2-리셉터 활성을 지닌 이것의 유사체, 내인성 히스타민 방출 제제 및 H2-리셉터 작동약으로 구성되는 군으로 부터 선택된 치료제를 포함하는 제1조성물과 IL-2를 포함하는 제2조성물을 사용하는 방법.
  7. 제6항에 있어서, 상기 치료제의 1일 용량은 0.1 내지 10mg, 바람직하게는 0.5 내지 8mg, 더욱 바람직하게는 1 내지 5mg인 것을 특징으로 하는 방법.
  8. 제6항 또는 제7항에 있어서, IL-2의 1일 용량은 1,000 내지 300,000U/kg, 바람직하게는 3,000 내지 100,000U/kg, 더욱 바람직하게는 5,000 내지 20,000/kg인 것을 특징으로 하는 방법.
  9. 제1항에 있어서, 상기 치료제는 히스타민인 것을 특징으로 하는 방법.
  10. 제6항 내지 제9항 중 어느 한항에 있어서, 용매, 분산 매체, 피복물, 살균제, 등장제 및 흡수 지연제와 같은 하나 이상의 제약학적 허용 담체를 함유하는 것을 특징으로 하는 방법.
  11. ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019920700628A 1989-09-19 1990-09-19 악성 종양세포의 전이 효소 및 종양 성장을 억제하기 위한 제약학적 제제 또는 시스템 및 그 사용방법 KR100195392B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40935789A 1989-09-19 1989-09-19
US409,357 1989-09-19
SE409,357 1989-09-19
PCT/SE1990/000599 WO1991004037A1 (en) 1989-09-19 1990-09-19 Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists

Publications (2)

Publication Number Publication Date
KR920703078A true KR920703078A (ko) 1992-12-17
KR100195392B1 KR100195392B1 (ko) 1999-06-15

Family

ID=23620128

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920700628A KR100195392B1 (ko) 1989-09-19 1990-09-19 악성 종양세포의 전이 효소 및 종양 성장을 억제하기 위한 제약학적 제제 또는 시스템 및 그 사용방법

Country Status (12)

Country Link
US (1) US5348739A (ko)
EP (1) EP0493468B1 (ko)
JP (1) JP2845622B2 (ko)
KR (1) KR100195392B1 (ko)
AT (1) ATE136786T1 (ko)
AU (1) AU640954B2 (ko)
CA (1) CA2066728C (ko)
DE (1) DE69026620T2 (ko)
DK (1) DK0493468T3 (ko)
ES (1) ES2087163T3 (ko)
NO (1) NO921050L (ko)
WO (1) WO1991004037A1 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107771A0 (en) * 1992-11-27 1994-02-27 Wellcome Found Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation
WO1996005289A1 (en) * 1994-08-08 1996-02-22 Syntello, Inc. Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
AU9794698A (en) 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
KR20010072957A (ko) * 1998-08-24 2001-07-31 추후보정 Ｈ2 수용체 작용제 및 기타 ｔ-세포 활성화제를 사용한ｔ-세포(ｃｄ4+ 및 ｃｄ8+) 활성화 및 보호 방법
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6153113A (en) 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
EP1200074A2 (en) * 1999-07-16 2002-05-02 Maxim Pharmaceuticals, Inc. Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
EP1536819A4 (en) * 2002-03-29 2007-10-17 Maxim Pharm Inc USING THE PRODUCTION OF REACTIVE OXYGEN METABOLITES (ROM) AND RELEASE INHIBITORS TO TREAT AND PREVENT INTRAOCULAR DAMAGE
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
JP2008531562A (ja) 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法
CN101316592A (zh) 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
JP2010520220A (ja) 2007-02-28 2010-06-10 イノテック ファーマシューティカルズ コーポレイション インデノイソキノリノン類似体およびその使用方法
WO2010120649A2 (en) * 2009-04-16 2010-10-21 Epicept Corporation Composition and use of n-alpha-methylhistamine dihydrochloride for the reduction of oxygen radical formation
US9617517B2 (en) 2011-05-02 2017-04-11 National University Corporation Kumamoto University Small chemical compound which promotes induction of differentiation of stem cells into insulin-producing cells and method for inducing differentiation of stem cells into insulin-producing cells using said small chemical compound
US20200222505A1 (en) * 2017-06-29 2020-07-16 Immune Pharmaceuticals, Inc. Methods of delaying and preventing acute myeloid leukemia relapse
WO2019023344A1 (en) * 2017-07-27 2019-01-31 Immune Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF METASTATIC TUMORS

Also Published As

Publication number Publication date
EP0493468B1 (en) 1996-04-17
EP0493468A1 (en) 1992-07-08
NO921050D0 (no) 1992-03-18
US5348739A (en) 1994-09-20
ATE136786T1 (de) 1996-05-15
AU640954B2 (en) 1993-09-09
JPH05504548A (ja) 1993-07-15
DK0493468T3 (da) 1996-08-26
AU6419190A (en) 1991-04-18
WO1991004037A1 (en) 1991-04-04
NO921050L (no) 1992-03-18
KR100195392B1 (ko) 1999-06-15
CA2066728A1 (en) 1991-03-20
ES2087163T3 (es) 1996-07-16
CA2066728C (en) 2001-12-25
DE69026620T2 (de) 1996-10-02
DE69026620D1 (de) 1996-05-23
JP2845622B2 (ja) 1999-01-13

Similar Documents

Publication Publication Date Title
KR920703078A (ko) 인터로이킨-2 및 히스타민, 이것의 유사물 또는 h₂-리셉터 작동약을 포함하는 항종양 제제
Cutts et al. Biological properties of Vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action
CA2136952C (en) Preparation for activation of natural killer cells (nk-cells), said preparation containing interferon-– and histamine, serotonin, amines or substances with corresponding receptor activity
Fukushima et al. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous iv infusion of 5-fluorouracil
Manheimer et al. Mitomycin‐C in the therapy of far‐advanced malignant tumors
HOSHI et al. Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil against L1210 leukemia
US6375946B1 (en) Enhanced activation of natural killer cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
Baldini et al. Antineoplastic activity of diazoacetyl-glycine derivatives
Bardakji et al. 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer: clinical, pharmacokinetic and in vitro cytotoxicity studies
EP0104826A2 (en) Immunomodulator and method of use for immunomodulation
Rustum Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience
ODASHIMA Development of liver cancers in the rat by 20-methylcholanthrene painting following initial 4-dimethylaminoazobenzene feeding
Wang et al. Inhibition of the induction of alloreactivity with mitoxantrone
Palomares et al. Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells
Umezawa Small molecular microbial products enhancing immune response
Tsuruo et al. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(γ-l-glutamylamino) ethyl] dithio] ethyl] mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo
US5525626A (en) Treating susceptible human malignant tumors with 7-hydroxy-1,2-benzopyrone
Stratford et al. The assessment of bioreductive drug toxicity in vitro and in experimental tumours in vivo
JPH07196490A (ja) 癌転移抑制剤
Holcenberg Enhanced Effect of an L-Glutamine Antagonist, L-(aS, 5S)-α-Amino-3-chloro-4, 5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-Glutaminase-L-Asparaginase ¹
HOSHI et al. ANTITUMOR ACTIVITY OF METABOLITES OF 1-HEXYLCAR-BAMOYL-5-FLUOROURACIL AND RELATED COMPOUNDS AGAINST L1210 LEUKEMIA IN VIVO AND L5178Y LYMPHOMA CELLS IN VITRO
Eckhardt Phase I and II studies with hexitol derivatives, formyl-leurosine and ftorafur
TOKUZEN et al. Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice
Hansen et al. Vindesine in the treatment of metastatic breast cancer
Robins Purine nucleoside 3′, 5′-cyclic monophosphates as hormonal modulators of cellular proliferation, metastases and lymphocyte response

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100210

Year of fee payment: 12

EXPY Expiration of term